Royal Bank of Canada Reiterates Outperform Rating for 4basebio (LON:4BB)

4basebio (LON:4BB)‘s stock had its “outperform” rating reiterated by equities research analysts at Royal Bank of Canada in a note issued to investors on Thursday, MarketBeat reports. They presently have a GBX 1,600 ($20.70) target price on the stock. Royal Bank of Canada’s price objective would suggest a potential upside of 41.34% from the stock’s current price.

4basebio Stock Performance

Shares of LON 4BB opened at GBX 1,132 ($14.64) on Thursday. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. The firm has a market cap of £145.01 million, a price-to-earnings ratio of -1,451.28 and a beta of 1.09. The business’s 50-day simple moving average is GBX 1,167.33 and its 200-day simple moving average is GBX 1,265.15. 4basebio has a 52 week low of GBX 901 ($11.65) and a 52 week high of GBX 1,820 ($23.54).

Insider Transactions at 4basebio

In other news, insider Amy Walker acquired 1,151 shares of the firm’s stock in a transaction dated Friday, February 28th. The shares were bought at an average price of GBX 1,120 ($14.49) per share, with a total value of £12,891.20 ($16,674.69). 68.44% of the stock is owned by insiders.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.